Doxycycline effectively targets a broad range of bacteria. Gram-positive bacteria susceptible include Streptococcus pneumoniae (some strains show resistance), Staphylococcus aureus (methicillin-sensitive strains), and Enterococcus faecalis (certain strains). However, resistance is a growing concern, necessitating susceptibility testing before treatment.
Against Gram-negative bacteria, doxycycline’s activity is notable. It effectively inhibits Chlamydia trachomatis, Chlamydia pneumoniae, Legionella pneumophila, and Haemophilus influenzae. Neisseria gonorrhoeae is also susceptible, although resistance is increasingly reported. Always consult current guidelines for local resistance patterns.
Doxycycline also demonstrates efficacy against several atypical bacteria including Mycoplasma pneumoniae and Rickettsia species, making it a valuable treatment option for respiratory and tick-borne illnesses. Its action against Borrelia burgdorferi, the causative agent of Lyme disease, is well-established.
However, doxycycline lacks activity against many anaerobic bacteria and enterococci. Furthermore, its use against Pseudomonas aeruginosa is generally discouraged due to widespread resistance.
Clinical Considerations: Always consider factors like patient allergies, pregnancy status, and potential drug interactions when prescribing doxycycline. Careful monitoring for side effects, such as photosensitivity and gastrointestinal upset, is advised. Dosage should be adjusted based on the infection and patient characteristics.
Note: This overview provides a general summary. Specific susceptibility profiles vary geographically and may change over time. Always refer to up-to-date antimicrobial susceptibility data and clinical guidelines to guide treatment decisions.
